We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Grassley Planning to Investigate Orphan Designation’s Impact on High Drug Prices
Grassley Planning to Investigate Orphan Designation’s Impact on High Drug Prices
Sen. Chuck Grassley (R-Iowa) is planning to examine the FDA’s orphan drug programs to find out if companies are using the designation to justify higher prices for common drugs.